Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Completed
814
2020-11
Industry sponsor intelligence
GlaxoSmithKlineClinical Pipeline.
Lead-sponsor view of GlaxoSmithKline's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 36
- Recruiting
- 0
- Active
- 0
- Completed
- 30
- Results posted
- 25
- Avg enrollment
- 516
Pipeline overview
Programs by phase and activity.
Velocity
GlaxoSmithKline trials by start year
Study start year · indexed snapshot
Development
Trials by phase
36phase labels
Early Phase 10
Phase 18
Phase 26
Phase 317
Phase 45
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Albiglutide → | 33 | 8 | 6 | 14 | 5 | 0 |
| Sincalide → | 1 | 0 | 0 | 0 | 1 | 0 |
| Atosiban → | 2 | 0 | 0 | 2 | 0 | 0 |
| Eptifibatide → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies
GlaxoSmithKline · Obstetric Labour, Premature
Phase 3
Completed
98
2020-07
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 1
Phase 2
Completed
67
2020-06
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Completed
308
2019-07
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus
Phase 4
Completed
9,463
2019-03
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 4
Completed
20
2018-04
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 1
Completed
34
2017-08
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 1
Completed
75
2017-07
A Drug Interaction Study With Albiglutide and Warfarin
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 1
Completed
16
2017-06
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 1
Completed
16
2017-06
Showing 10 of 30 studies
Search sponsor records
All GlaxoSmithKline studies.
This page groups studies where GlaxoSmithKline is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
36 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT02229227Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes MellitusNov 27, 2020NCT02793154An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus SubjectsOct 30, 2020NCT02802514A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy SubjectsOct 30, 2020NCT02292771A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm LabourJul 29, 2020NCT02292784Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment StudiesJul 9, 2020NCT02284009Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes MellitusJun 29, 2020NCT02683746Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes MellitusJul 23, 2019NCT02750930Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus SubjectsJul 12, 2019NCT02465515Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusMar 6, 2019NCT03015519A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes MellitusJan 17, 2019